For: | Piché A. Malignant peritoneal effusion acting as a tumor environment in ovarian cancer progression: Impact and significance. World J Clin Oncol 2018; 9(8): 167-171 [PMID: 30622924 DOI: 10.5306/wjco.v9.i8.167] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v9/i8/167.htm |
Number | Citing Articles |
1 |
Caroline Elizabeth Ford, Bonnita Werner, Neville Frederick Hacker, Kristina Warton. The untapped potential of ascites in ovarian cancer research and treatment. British Journal of Cancer 2020; 123(1): 9 doi: 10.1038/s41416-020-0875-x
|
2 |
Corinna Steidel, Fanny Ender, Achim Rody, Nikolas von Bubnoff, Frank Gieseler. Biologically Active Tissue Factor-Bearing Larger Ectosome-Like Extracellular Vesicles in Malignant Effusions from Ovarian Cancer Patients: Correlation with Incidence of Thrombosis. International Journal of Molecular Sciences 2021; 22(2): 790 doi: 10.3390/ijms22020790
|
3 |
Mariana Nunes, Sara Ricardo. Ovarian Cancer. 2022; : 27 doi: 10.36255/exon-publications-ovarian-cancer-malignant-ascites
|
4 |
Militsa Rakina, Anna Kazakova, Alisa Villert, Larisa Kolomiets, Irina Larionova. Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components. International Journal of Molecular Sciences 2022; 23(11): 6215 doi: 10.3390/ijms23116215
|
5 |
Marta Brunetti, Ioannis Panagopoulos, Ilyá Kostolomov, Ben Davidson, Sverre Heim, Francesca Micci. Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer. Oncology Letters 2020; 20(3): 2273 doi: 10.3892/ol.2020.11782
|
6 |
Sarai Tomás-Pérez, Julia Oto, Cristina Aghababyan, Raquel Herranz, Aitor Cuadros-Lozano, Eva González-Cantó, Bárbara Mc Cormack, Judith Arrés, María Castaño, Fernando Cana, Laura Martínez-Fernández, Núria Santonja, Rocío Ramírez, Alejandro Herreros-Pomares, Sarai Cañete-Mota, Antoni Llueca, Josep Marí-Alexandre, Pilar Medina, Juan Gilabert-Estellés. Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients’ biofluids: Potential role in disease diagnosis and management. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1111344
|
7 |
Bonnita Werner, Nicole Yuwono, Jennifer Duggan, Dongli Liu, Catherine David, Sivatharsny Srirangan, Pamela Provan, Anna DeFazio, Vivek Arora, Rhonda Farrell, Yeh Chen Lee, Kristina Warton, Caroline Ford. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. Gynecologic Oncology 2021; 162(3): 720 doi: 10.1016/j.ygyno.2021.06.028
|
8 |
薇 周. The Value of Ascites Cytology in the Diagnosis of Ovarian Malignant Tumors. Advances in Clinical Medicine 2023; 13(05): 7809 doi: 10.12677/ACM.2023.1351091
|
9 |
O. I. Aleshikova, N. A. Babaeva, E. V. Gerfanova, I. B. Antonova, V. O. Shender, A. E. Babaeva, L. A. Ashrafyan. Ovarian cancer, malignant ascites and microenvironment. Literature review. Sechenov Medical Journal 2023; 14(2): 21 doi: 10.47093/2218-7332.2023.14.2.21-30
|
10 |
Pascale Ribaux, Aurore Britan, Gabriele Thumann, Florence Delie, Patrick Petignat, Marie Cohen. Malignant ascites: a source of therapeutic protein against ovarian cancer?. Oncotarget 2019; 10(57): 5894 doi: 10.18632/oncotarget.27185
|
11 |
Bingsi Gao, Xingping Zhao, Pan Gu, Dan Sun, Xinyi Liu, Waixing Li, Aiqian Zhang, Enuo Peng, Dabao Xu. A nomogram model based on clinical markers for predicting malignancy of ovarian tumors. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.963559
|